Long non-coding RNA LRTOR drives osimertinib resistance in non-small cell lung cancer by boosting YAP positive feedback loop
Drug Resistance Updates · 2025-11 · 83 · 101245
DOI: 10.1016/j.drup.2025.101245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2025-11. Verfasst von Zhimin Miao und 19 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao SAR 999078, Ch…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms, RNA, Long Noncoding. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Macau, Fundo para o Desenvolvimento das Ciências e da Tecnologia.
Abstract (Originalsprache)
The therapeutic efficacy of osimertinib (OSI) in EGFR-mutant lung cancer is ultimately limited by the onset of acquired resistance, of which the mechanisms remain poorly understood. Here, we identify a novel long non-coding RNA, LRTOR, as a key driver of OSI resistance in non-small cell lung cancer (NSCLC). Clinical data indicate that elevated LRTOR expression correlates with poor prognosis in OSI-resistant patients. Functionally, LRTOR promotes tumor growth and confers OSI resistance both in vitro and in vivo. Mechanistically, LRTOR shields YAP from LATS-mediated phosphorylation at Ser127 and Ser381, preventing its proteasomal degradation. Furthermore, LRTOR facilitates the interaction between YAP and KCMF1, promoting K63-linked ubiquitination, nuclear translocation of YAP, and formation of the YAP/TEAD1 transcriptional complex, which in turn triggers the transcription of LRTOR, establishing a positive feedback loop that amplifies oncogenic signaling of YAP and consequently induces OSI resistance. LRTOR depletion by siRNA restores OSI sensitivity in resistant tumors, as demonstrated in patient-derived organoid xenograft models. Our findings unveil LRTOR as a central regulator of OSI resistance in NSCLC and propose it as a promising therapeutic and prognostic target for overcoming acquired OSI resistance in EGFR-mutant lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao SAR 999078, China; Department of Pharmaceutical Sciences, Faculty of Health Sciences…
- Department of Thoracic Oncology, The Cancer Center of The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China.
- Department of Pathology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China.
- Department of Thoracic Oncology, The Cancer Center of The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China. Electronic address: peixf3@mail.sysu.edu.cn.
Förderung
- University of Macau
- Fundo para o Desenvolvimento das Ciências e da Tecnologia
Zitieren
APA
Miao, Z., Sha, Z., He, J., Liang, Y., Tan, L., Zhao, Y., Cui, X., Zhong, J., Zhong, R., Liang, H., Yue, W., Qiu, B., Gao, Y., Zhang, L., Teng, Z., He, Z., Chen, L., Xiao, R., Pei, X., & He, C. (2025). Long non-coding RNA LRTOR drives osimertinib resistance in non-small cell lung cancer by boosting YAP positive feedback loop. Drug Resistance Updates, 83, 101245. https://doi.org/10.1016/j.drup.2025.101245
Vancouver
Miao Z, Sha Z, He J, Liang Y, Tan L, Zhao Y, et al. Long non-coding RNA LRTOR drives osimertinib resistance in non-small cell lung cancer by boosting YAP positive feedback loop. Drug Resistance Updates. 2025;83:101245. doi:10.1016/j.drup.2025.101245
BibTeX
@article{Miao2025,
author = {Miao, Zhimin and Sha, Zhou and He, Jianzhong and Liang, Yongkai and Tan, Lihua and Zhao, Yuxin and Cui, Xiaobing and Zhong, Jinmiao and Zhong, Ruting and Liang, Huijun and Yue, Wendi and Qiu, Boyang and Gao, Yunzhen and Zhang, Lan and Teng, Zixin and He, Zeen and Chen, Li and Xiao, Rufei and Pei, Xiaofeng and He, Chengwei},
title = {Long non-coding RNA LRTOR drives osimertinib resistance in non-small cell lung cancer by boosting YAP positive feedback loop},
journal = {Drug Resistance Updates},
year = {2025},
volume = {83},
pages = {101245},
doi = {10.1016/j.drup.2025.101245}
}
EUVIMED